二重特異性抗体市場：作用機序、治療領域、エンドユーザー別-2024-2030年の世界予測

二重特異性抗体市場規模は2023年に43億6,000万米ドルと推計され、2024年には61億4,000万米ドルに達し、CAGR 42.24%で2030年には514億7,000万米ドルに達すると予測されています。

二重特異性抗体（BsAbs）は、2つの異なるタイプの抗原または同じ抗原上の2つの異なるエピトープに同時に結合することができる人工タンパク質です。この二重標的能力は、単一の抗原に結合するように開発された従来のモノクローナル抗体とは一線を画しています。二重特異性抗体の主な用途は治療領域であり、特にがん細胞を標的とし、中和することです。そのユニークな能力により、エフェクター細胞をがん細胞に近づけ、がんと闘う免疫系の能力を高めることができます。さらに、病気のメカニズムを理解するための調査での使用は、自己免疫疾患や炎症性疾患に対するより効果的な治療法の開発への応用とさらに一致します。二重特異性抗体市場の成長には、世界のがんやその他の慢性疾患の罹患率の上昇、遺伝子工学やタンパク質工学技術の進歩、新規二重特異性抗体を開発・承認するための革新的治療法に対する規制当局の支援の拡大など、いくつかの要因が寄与しています。しかし、二重特異性抗体の開発は高コストであり、二重特異性抗体の製造は複雑であるため、二重特異性抗体の拡大は妨げられています。一方、二重特異性抗体の希少疾患治療への利用が拡大し、製薬会社によるヘルスケアインフラや研究開発活動への投資が増加していることが、二重特異性抗体市場に新たな道を開いています。

作用機序：オフターゲット効果を最小化するデュアル抗原ターゲティングへの嗜好の高まり

デュアル抗原ターゲティング二重特異性抗体は、細胞表面上の2つの異なる抗原に同時に結合するように設計されています。このメカニズムは、結合のために標的が存在しなければならないことを保証することによって選択性と有効性を高め、それによって標的外効果を最小限に抑え、治療成績を向上させます。複数の経路が病気の進行を促進する、がんなどの複雑な病気で必要となります。デュアルブロッキング抗体は、2つの異なるシグナル伝達経路の作用を同時に阻害します。2つの異なるリガンドやレセプターを阻害することで、これらの抗体は、特にがんや自己免疫疾患などの疾患において、より効果的に病態プロセスを遮断することができます。シグナル伝達経路に冗長性があるために単一標的薬剤の有効性が損なわれるような状況では、二重遮断抗体の必要性に基づく嗜好性が明らかになります。T細胞エンゲイジャーは、細胞傷害性T細胞を腫瘍細胞に近接させ、腫瘍の標的殺傷を促進するようにデザインされた二重特異性抗体のサブセットです。T細胞エンゲイジャーの必要性に基づく選好は、患者の免疫系をがんと闘うために利用する能力が転帰を著しく改善する腫瘍学において特に強いです。これらのメカニズムを比較すると、二重抗原を標的とするbsAbsは選択性を高めるという利点があり、よく特徴付けられた特異的な病理学的マーカーを持つ疾患に特に適しています。二重抗原阻害抗体は、複数の経路を標的とすることで、経路の冗長性や代償的な病態進行機序を特徴とする疾患において、治療成績の向上を約束します。T細胞エンゲイジャーは、腫瘍に対して免疫系を動員することによってユニークなアプローチを提供し、腫瘍学において大きな可能性を示しますが、潜在的な免疫介在毒性については慎重な管理が必要です。

治療領域：がん細胞への関与と破壊を目的とした、がん領域における二重特異性抗体の応用拡大

二重特異性抗体のデュアルターゲット能力は、健康な組織を温存しながら、がん細胞に関与し破壊する強力なメカニズムを提供します。腫瘍学におけるbsAbsの使用は、腫瘍抗原の標的化から免疫エフェクター細胞のがんに対するより指向性の高い免疫応答への関与に及びます。自己免疫疾患においては、二重特異性抗体（bsAbs）が標的免疫療法の有望なアプローチとなります。これらの分子は、2つの異なる抗原やエピトープに同時に結合するように調整されており、免疫応答を正確に調節することができます。広範な免疫抑制作用なしに選択的な免疫抑制を実現し、感染症や悪性腫瘍のリスクを軽減することが求められています。複数のターゲットに作用する二重特異性抗体のユニークな能力は、感染症、特に免疫系の回避が重要な課題であるHIVを含むウイルス感染症に対抗する可能性を持っています。これらの治療法は、同時にウイルスのエピトープを標的とし、免疫細胞をリクルートすることにより、抗ウイルス反応を高めることができます。二重特異性抗体は、神経抗原の正確なターゲティングを可能にし、神経治療における重要な課題である血液脳関門（BBB）の通過を促進することにより、神経疾患の治療における新たな道筋を提供します。がん領域では、臨床開発中のbsAbsの応用が最も進んでおり、その種類も多岐にわたっています。これは、標的がん治療に対する高いニーズと、この領域への多額の投資によるものです。自己免疫疾患と神経疾患は、bsAbsが従来の治療法に比べて新しい作用機序を提供できる成長分野です。感染症は現在開発中のbsAbsが少なく、特に標準治療に抵抗性の慢性ウイルス感染症において画期的な治療法の可能性を示しています。

地域別の洞察

米国は、強固な研究開発インフラ、多額のヘルスケア支出、強力な特許ポートフォリオに支えられ、市場の需要と二重特異性抗体開発の最前線にあります。FDAの支援的な規制の枠組みは革新的な治療法の承認を加速させ、BsAbsに特化したバイオテクノロジー企業への多額の投資を促しています。カナダでは、二重特異性抗体療法への関心が高まっており、研究機関やバイオテクノロジー新興企業が政府や民間からの資金援助を受けています。二重特異性抗体の南米市場はまだ発展途上の段階にありますが、ヘルスケア支出の増加、革新的ながん治療に対する意識の高まり、医療インフラの改善がこの地域の市場拡大に寄与しており、大きな成長の可能性を示しています。欧州連合では、二重特異性抗体を含む高度な治療ソリューションの導入に重点が置かれています。新しい治療法の承認、高額な医療費、患者の意識に対する EMA (欧州医薬品庁) の積極的なアプローチにより、BsAb にとって好ましい環境が促進されています。中東およびアフリカでは、医療インフラが限定的で医療支出が少ないことが主な理由で、二重特異性抗体の採用が遅れています。しかし、UAEやサウジアラビアなどの中東諸国はヘルスケア分野で躍進しており、二重特異性抗体市場に刺激を与える可能性があります。アジア太平洋地域は二重特異性抗体市場の著しい成長を目の当たりにしています。医療費の高騰、がん罹患率の上昇、先進治療に対する意識の高まりがその背景にあります。中国と日本が最前線で二重特異性抗体の研究開発を先導しています。規制改革、ヘルスケアインフラの拡大、地元のバイオテクノロジー企業と国際的な製薬大手との提携は、アジア太平洋市場を推進する重要な要因です。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、二重特異性抗体市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、二重特異性抗体市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.二重特異性抗体市場の市場規模および予測は？

2.二重特異性抗体市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.二重特異性抗体市場の技術動向と規制枠組みは？

4.二重特異性抗体市場における主要ベンダーの市場シェアは？

5.二重特異性抗体市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でがんやその他の慢性疾患の発生率が上昇
    • 遺伝子工学とタンパク質工学技術の進歩
    • 新規二重特異性抗体の開発と承認のための革新的な治療法に対する規制上の支援拡大
  • 抑制要因
    • 二重特異性抗体の開発にかかるコストが高い
  • 機会
    • 希少疾患の治療における二重特異性抗体の利用拡大
    • 製薬会社によるヘルスケアインフラと研究開発活動への投資増加
  • 課題
    • 二重特異性抗体に関連する製造の複雑さ
• 市場セグメンテーション分析
  • 作用機序：オフターゲット効果を最小限に抑えるために二重抗原標的化の優先度が高まっている
  • 治療領域：がん細胞を攻撃し破壊するための腫瘍学における二重特異性抗体の応用拡大
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 二重特異性抗体市場：作用機序別

• 二重抗原標的
• 二重阻害抗体
• T細胞エンゲージャー

第7章 二重特異性抗体市場：治療領域別

• 自己免疫疾患
• 感染症
• 神経学的障害
• 腫瘍学

第8章 二重特異性抗体市場：エンドユーザー別

• 病院と専門医
• 調査機関および学術センター

第9章 南北アメリカの二重特異性抗体市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の二重特異性抗体市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの二重特異性抗体市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析（2023年）
• FPNVポジショニングマトリックス（2023年）
• 競合シナリオ分析
  • AstraZenecaは「2.0」がんパイプラインを目指し、二重特異性データを共有
  • 米国FDA、多発性骨髄腫の重篤な前治療歴を持つ患者の治療のための二重特異性療法TALVEY（TM）（タルケタマブ-TGV）を承認
  • PfizerのエルラナタマブがFDAとEMAの申請受理を受ける
• 戦略分析と提言

第13章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. BISPECIFIC ANTIBODIES MARKET RESEARCH PROCESS
• FIGURE 2. BISPECIFIC ANTIBODIES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. BISPECIFIC ANTIBODIES MARKET DYNAMICS
• FIGURE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BISPECIFIC ANTIBODIES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL ANTIGEN TARGETING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL ANTIGEN TARGETING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL-BLOCKING ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL-BLOCKING ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY T-CELL ENGAGERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY T-CELL ENGAGERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY HOSPITALS & SPECIALIST CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY HOSPITALS & SPECIALIST CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMIC CENTERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMIC CENTERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 32. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 33. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 34. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 35. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 36. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 37. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 38. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 39. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 40. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 41. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 42. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 43. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 44. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 45. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 46. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 47. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 48. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 49. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 50. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 51. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 52. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 53. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 54. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 55. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 56. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 57. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 58. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 59. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 60. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 61. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 62. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 63. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 64. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 65. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 66. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 67. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 68. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 69. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 70. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 72. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 74. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 76. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 78. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 79. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 80. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 81. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 82. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 83. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 84. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 85. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 86. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 87. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 88. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 89. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 90. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 91. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 92. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 93. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 94. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 95. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 96. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 97. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 98. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 99. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 100. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 101. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 102. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 103. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 104. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 105. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 106. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 107. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 108. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 109. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 110. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 111. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 112. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 113. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 114. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 115. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 116. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 117. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 118. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 119. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 120. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 121. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 122. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 123. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 124. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 125. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 126. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 128. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 130. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 132. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 133. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 134. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 135. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 136. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 137. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 138. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 139. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 140. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 141. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 142. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 143. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 144. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 145. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 146. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 147. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 148. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 149. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 150. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 159. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 160. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 161. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 162. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 163. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 164. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 165. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 166. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 167. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 168. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 169. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 170. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 171. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 172. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 173. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 174. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 175. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 176. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 177. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 178. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 179. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 180. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 181. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 182. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 183. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 184. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 185. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 186. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 187. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 188. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 189. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 190. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 191. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 192. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 193. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 194. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 195. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 196. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 197. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 198. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 199. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 200. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 201. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 202. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 203. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 204. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 205. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 206. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 207. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 208. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 209. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 210. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 211. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 212. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 213. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 214. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 215. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 216. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 217. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 218. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 219. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 220. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 221. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 222. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 223. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 224. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 225. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 226. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 227. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 228. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 229. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 230. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 231. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 232. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 233. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 234. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 235. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 236. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 238. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 240. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 242. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 244. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 246. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 248. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 249. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 250. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 251. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 252. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 253. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 254. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 255. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 256. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 257. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 258. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 259. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 260. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 261. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 262. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 263. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 264. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 265. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 266. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 267. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 268. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 269. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 270. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 271. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 272. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
• TABLE 280. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 282. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 284. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 285. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 286. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

[192 Pages Report] The Bispecific Antibodies Market size was estimated at USD 4.36 billion in 2023 and expected to reach USD 6.14 billion in 2024, at a CAGR 42.24% to reach USD 51.47 billion by 2030.

Bispecific antibodies (BsAbs) are engineered proteins that can simultaneously attach to two different types of antigens or two different epitopes on the same antigen. This dual-targeting ability distinguishes them from traditional monoclonal antibodies developed to bind to a single antigen. The primary applications of bispecific antibodies reside in the therapeutic domain, particularly in targeting and neutralizing cancer cells. Their unique capability allows them to bring effector cells in close proximity to cancer cells, enhancing the immune system's ability to combat cancer. Additionally, their use in research to understand disease mechanisms further aligns with their application in creating more effective treatments for autoimmune and inflammatory diseases. Several factors contribute to the growth of the bispecific antibodies market, including rising incidences of cancer and other chronic illnesses globally, advancements in genetic engineering and protein engineering technologies, and growing regulatory support for innovative therapies for developing and approving novel bispecific antibodies. However, the expansion of bispecific antibodies is hindered by the high costs of the development of bispecific antibodies and the manufacturing complexities associated with bispecific antibodies. On the other hand, expanding usage of bispecific antibodies in the treatment of rare diseases and rising investments in healthcare infrastructure and research & development activities by pharmaceutical companies opens new avenues for the bispecific antibodies market.

Mechanism of Action: Increasing preference for dual antigen targeting for minimizing off-target effects

Dual antigen-targeting bispecific antibodies are designed to bind to two distinct antigens on the surface of cells simultaneously. This mechanism enhances selectivity and efficacy by ensuring that targets must be present for binding, thereby minimizing off-target effects and improving therapeutic outcomes. It is needed in complex diseases, including cancer, where multiple pathways drive disease progression. Dual-blocking antibodies inhibit the action of two separate signaling pathways simultaneously. By blocking two different ligands or receptors, these antibodies can more effectively shut down pathological processes, especially in diseases such as cancer and autoimmune disorders. Need-based preference for dual-blocking antibodies becomes apparent in conditions where redundancy in signaling pathways can undermine the efficacy of single-target agents. T-cell engagers represent a subset of bispecific antibodies designed to bring cytotoxic T-cells into close proximity with tumor cells, thereby promoting the targeted killing of the tumor. Need-based preference for T-cell engagers is particularly strong in oncology, where the ability to harness the patient's immune system to fight cancer can significantly improve outcomes. In comparing these mechanisms, dual antigen-targeting bsAbs offer the advantage of enhanced selectivity, making them particularly suitable for diseases with well-characterized and specific pathological markers. Dual-blocking antibodies, by targeting multiple pathways, promise improved therapeutic outcomes in diseases characterized by pathway redundancy or compensatory mechanisms of disease progression. T-cell engagers offer a unique approach by mobilizing the immune system against tumors, showing great promise in oncology but requiring careful management of potential immune-mediated toxicities.

Therapeutic Area: Expanding application of bispecific antibodies in oncology for engaging and destroying cancer cells

Oncology remains the most prolific area for the application of bispecific antibodies, with their dual-targeting ability offering a potent mechanism for engaging and destroying cancer cells while sparing healthy tissue. The use of bsAbs in oncology spans targeting tumor antigens to engaging immune effector cells for a more directed immune response against cancer. In autoimmune diseases, bispecific antibodies (bsAbs) pose a promising approach for targeted immunotherapy. These molecules are tailored to bind two different antigens or epitopes simultaneously, allowing precision in modulating immune responses. The need lies in achieving selective immunosuppression without broad immunosuppressive effects, thus reducing the risk of infections and malignancies. The unique capability of bispecific antibodies to engage multiple targets holds potential in combating infectious diseases, particularly viral infections, including HIV, where evasion of the immune system is a significant challenge. These therapies can simultaneously target viral epitopes and recruit immune cells, thereby enhancing the antiviral response. Bispecific antibodies offer a novel pathway in treating neurological disorders by enabling precise targeting of neural antigens and facilitating the cross of the blood-brain barrier (BBB), a significant challenge in neurotherapeutics. The oncology sector exhibits the most advanced application and diverse range of bsAbs under clinical development, which is attributed to the high need for targeted cancer therapies and the significant investment in this area. Autoimmune diseases and neurological disorders represent growing segments where bsAbs can offer novel mechanisms of action compared to traditional therapies. Infectious diseases currently have fewer bsAbs under development and show potential for groundbreaking therapies, especially in chronic viral infections resistant to standard treatment.

Regional Insights

The United States is at the forefront of the market demand and the development of bispecific antibodies, backed by robust R&D infrastructure, significant healthcare spending, and a strong patent portfolio. The FDA's supportive regulatory framework accelerates the approval of innovative therapies, encouraging substantial investments in biotechnology firms focused on BsAbs. Canada showcases a growing interest in bispecific antibody therapies, with research institutions and biotech startups receiving government and private funding. The South American market for bispecific antibodies is in a nascent stage; however, it exhibits potential for significant growth due to increasing healthcare expenditure, rising awareness about innovative cancer treatments, and improving healthcare infrastructure, contributing to the market expansion in this region. In the European Union, there's a strong emphasis on the adoption of advanced therapeutic solutions, including bispecific antibodies. The EMA's (European Medicines Agency) proactive approach to approving novel treatments and high healthcare expenditure and patient awareness fosters a favorable environment for BsAbs. The Middle East and Africa show a slower adoption of bispecific antibodies, primarily due to limited healthcare infrastructure and lower healthcare spending. However, certain countries in the Middle East, such as UAE and Saudi Arabia, are making strides in the healthcare sector, which could provide an impetus to the bispecific antibodies market. The APAC region is witnessing remarkable growth in the bispecific antibodies market, driven by escalating healthcare expenditure, rising cancer incidence, and growing awareness about advanced therapies. China and Japan are at the forefront, spearheading research and development in the bispecific antibodies. Regulatory reforms, expanding healthcare infrastructures, and partnerships between local biotech firms and international pharmaceutical giants are key factors propelling the market in APAC.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Bispecific Antibodies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Bispecific Antibodies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Bispecific Antibodies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adimab, LLC, Affimed GmbH, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd., Genmab A/S, Gilead Sciences, Inc., Innovent Biologics, Janssen Global Services, LLC by Johnson & Johnson Pte. Ltd., MacroGenics, Inc., Merck KGaA, Mereo Biopharma Group PLC, Merus N.V., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., TG Therapeutics, Inc., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Bispecific Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Mechanism of Action
  • Dual Antigen Targeting
  • Dual-Blocking Antibodies
  • T-cell Engagers

• Therapeutic Area
  • Autoimmune Diseases
  • Infectious Diseases
  • Neurological Disorders
  • Oncology

• End-user
  • Hospitals & Specialist Clinics
  • Research Institutions & Academic Centers

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Bispecific Antibodies Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Bispecific Antibodies Market?

3. What are the technology trends and regulatory frameworks in the Bispecific Antibodies Market?

4. What is the market share of the leading vendors in the Bispecific Antibodies Market?

5. Which modes and strategic moves are suitable for entering the Bispecific Antibodies Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of cancer and other chronic illnesses globally
    • 5.1.1.2. Advancements in genetic engineering and protein engineering technologies
    • 5.1.1.3. Growing regulatory support for innovative therapies for the development and approval of novel bispecific antibodies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost regarding the development of bispecific antibodies
  • 5.1.3. Opportunities
    • 5.1.3.1. Expanding usage of bispecific antibodies in the treatment of rare diseases
    • 5.1.3.2. Rising investments in healthcare infrastructure and research & development activities by pharmaceutical companies
  • 5.1.4. Challenges
    • 5.1.4.1. Manufacturing complexities associated with bispecific antibodies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Mechanism of Action: Increasing preference for dual antigen targeting for minimizing off-target effects
  • 5.2.2. Therapeutic Area: Expanding application of bispecific antibodies in oncology for engaging and destroying cancer cells
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Bispecific Antibodies Market, by Mechanism of Action

• 6.1. Introduction
• 6.2. Dual Antigen Targeting
• 6.3. Dual-Blocking Antibodies
• 6.4. T-cell Engagers

7. Bispecific Antibodies Market, by Therapeutic Area

• 7.1. Introduction
• 7.2. Autoimmune Diseases
• 7.3. Infectious Diseases
• 7.4. Neurological Disorders
• 7.5. Oncology

8. Bispecific Antibodies Market, by End-user

• 8.1. Introduction
• 8.2. Hospitals & Specialist Clinics
• 8.3. Research Institutions & Academic Centers

9. Americas Bispecific Antibodies Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Bispecific Antibodies Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Bispecific Antibodies Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. AstraZeneca aims for '2.0' cancer pipeline, shares bispecific data
  • 12.3.2. U.S. FDA Approves TALVEY(TM) (talquetamab-tgvs), a Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
  • 12.3.3. Pfizer's Elranatamab Receives FDA and EMA Filing Acceptance
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio